Icagen Transaction

Important Information for Investors

Effective October 27, 2011 Pfizer Inc. completed its acquisition of Icagen, Inc. Pursuant to the terms of the merger, former Icagen shareholders will receive $6.00, in cash (without interest and less any applicable withholding and transfer taxes) for each share of Icagen common stock they owned as of the effective time of the merger.

Pfizer has appointed American Stock Transfer & Trust Company, LLC as paying agent for payment of the merger consideration. Additional information will be mailed to Icagen registered shareholders outlining the steps to be taken to obtain the merger consideration. Shareholders do not need to take any action regarding their shares until contacted by the paying agent. For additional information, please contact American Stock & Trust Company at 877-248-6417 or +1 718-921-8317.